Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy

Massimo Lopez, Paola Papaldo, Luigi Di Lauro, Mario Barduagni, Carlo Federico Perno, Aldo Barduagni

Research output: Contribution to journalArticlepeer-review

Abstract

43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.

Original languageEnglish
Pages (from-to)244-247
Number of pages4
JournalOncology
Volume40
Issue number4
DOIs
Publication statusPublished - 1983

Keywords

  • Breast cancer
  • Chemotherapy
  • Mitomycin C

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy'. Together they form a unique fingerprint.

Cite this